Pannysylvania Magazine

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Epilepsy Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market.

Some of the key takeaways from the Epilepsy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years.

• Epilepsy companies working in the treatment market are Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others, are developing therapies for the Epilepsy treatment

• Emerging Epilepsy therapies in the different phases of clinical trials are- LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others are expected to have a significant impact on the Epilepsy market in the coming years.

• In October 2026, Cadence Neuroscience receives FDA authorization for epilepsy device study: The FDA approved an Investigational Device Exemption (IDE) for the Biomarker Targeted Stimulation for Epileptiform Events (BTSEE) study. The multicenter clinical study will evaluate investigational biomarker-targeted stimulation therapy in 45 pediatric and adult patients with focal drug-resistant epilepsy at up to 10 US epilepsy centers. The study is intended to generate evidence for a potential future Humanitarian Device Exemption (HDE) application. This is authorization to conduct a clinical study, not approval to market the therapy.

• In September 2026, Xenon Pharmaceuticals submits NDA for azetukalner: Xenon submitted a New Drug Application (NDA) to the FDA for azetukalner for focal seizures in patients with epilepsy. The submission was supported by positive results from the Phase IIb X-TOLE and Phase III X-TOLE2 studies, which demonstrated statistically significant reductions in monthly seizure frequency compared with placebo. If approved, azetukalner could offer a new oral treatment option for patients with focal seizures.

• In Septemnber 2026, FDA places partial clinical hold on opakalim trials: The FDA paused new patient enrollment in Biohaven’s clinical trials of opakalim, an investigational Kv7.2/7.3 channel activator being developed for epilepsy. The action followed concerns about a metabolite identified in rodent studies, for which the FDA requested additional information. Existing participants could continue treatment, while the company worked to address the agency’s concern

• In August 2026, Jazz Pharmaceuticals expands its rare epilepsy pipeline: Jazz announced an agreement to acquire Actio Biosciences, adding ABS-1230, an investigational KCNT1 inhibitor, to its portfolio. ABS-1230 is being developed as a precision treatment for KCNT1-related developmental and epileptic encephalopathy, a rare genetic epilepsy associated with early-onset and often treatment-resistant seizures. The announcement represented a pipeline expansion rather than a drug approval.

• In July 2026, FDA requests additional evidence for NeuroPace RNS System indication expansion: NeuroPace reported that the FDA considered its application to expand the RNS System indication to patients with drug-resistant idiopathic generalized epilepsy not approvable in its current form. The agency requested additional clinical evidence supporting the application, including evidence from the NAUTILUS trial. The company intended to continue discussions with the FDA to determine a path forward.

• In June 2026, Biohaven completes enrollment in the pivotal RISE3 trial: Biohaven completed enrollment in its Phase II/III RISE3 study evaluating opakalim in patients with refractory focal epilepsy. The randomized, double-blind, placebo-controlled study was designed to assess efficacy and safety, with top-line results expected in the second half of 2026.

• In May 2026, Opakalim shows promising seizure-control findings: Biohaven reported clinical data from a randomized, placebo-controlled study in idiopathic generalized epilepsy. The median time to the second day with a generalized tonic-clonic seizure was 141 days with opakalim 75 mg once daily, compared with 47 days with placebo. Additional open-label data in focal epilepsy showed that 54% of participants receiving the 75 mg dose achieved at least a 50% reduction in seizure frequency over a consecutive six-month period. These findings remain investigational.

• In March 2026, Xenon Pharmaceuticals announced plans to seek U.S. approval for its investigational epilepsy treatment Azetukalner (XEN1101) after a late-stage study demonstrated that the therapy significantly reduced seizures in patients with difficult-to-treat forms of Epilepsy. Following the announcement, the company’s shares rose by about 48% on Monday. The biotech company also stated that it intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the third quarter, supported by results from the X-TOLE2 Trial evaluating the drug in patients with Focal Onset Seizures.

• In September 2025, Actio Biosciences has given the first dose to a participant in the Phase Ia clinical trial of ABS-1230, a KCNT1 (potassium sodium-activated channel subfamily T member 1) inhibitor designed for epilepsy treatment. The trial is a double-blind, randomized, placebo-controlled study assessing single and multiple ascending doses and the impact of food in healthy volunteers. Conducted in Australia, the study will evaluate the pharmacokinetics, safety, and tolerability of ABS-1230.

• In June 2025, Epiminder, a leader in implantable continuous EEG monitoring (iCEM™), has announced the publication of findings from its pivotal UMPIRE (sUb-scalp Monitoring ePileptic seIzuREs) trial in Epilepsia. The study, carried out at major hospitals in Australia, confirmed the safety and effectiveness of iCEM™, showing that the system can record high-quality EEG data over long durations, comparable to conventional scalp-based EEG monitoring.

• In May 2025, Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotech company focused on developing small molecule precision therapies for neurological and psychiatric conditions, announced its financial results for the first quarter ending March 31, 2025, along with a business update. The company described 2025 as a pivotal year, as it moves toward presenting initial proof-of-concept data for RAP-219 from its Phase 2a trial in patients with refractory focal epilepsy and advances its pipeline-in-a-product approach by launching a clinical trial for bipolar mania.

• In April 2025, In a Phase Ib/IIa trial, Lundbeck’s receptor superagonist, developed to treat seizures linked to developmental and epileptic encephalopathies (DEEs), demonstrated a 61.2% reduction in total seizures. Interim data from the open-label extension (OLE) of the Pacific trial (NCT05364021), which evaluated bexicaserin, an oral 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, in patients previously on placebo, revealed a 57.3% decrease in countable motor seizures and a 61.2% reduction in total seizures in those who had switched from placebo.

Epilepsy Overview

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. It can affect people of all ages and may result from genetic factors, brain injuries, infections, stroke, or other underlying conditions. Common symptoms include involuntary movements, temporary loss of awareness, confusion, and loss of consciousness. Treatment primarily involves anti-seizure medications, while surgery and neurostimulation may be considered for patients whose seizures are not adequately controlled with medication. With appropriate diagnosis and treatment, up to 70% of people with epilepsy could become seizure-free.

Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/epilepsy-pipeline-insight

Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:

• Kv7 Program: Elium Therapeutics

• CG 01: CombiGene

• OV329: Ovid Therapeutics

• OPC-214870: Otsuka Pharmaceutical Co.,Ltd.

• SKL24741: SK Biopharmaceuticals

• RLS103: Receptor Life Sciences

• CT-010: Cerebral Therapeutics

• EQU 001: Equilibre Biopharmaceuticals

• Darigabat: Cerevel Therapeutics

• ENX-101: Engrail Therapeutics

• AMZ002: Amzell

• XEN496: Xenon Pharmaceuticals Inc

Epilepsy Route of Administration

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Epilepsy Molecule Type

Epilepsy Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Epilepsy Pipeline Therapeutics Assessment

• Epilepsy Assessment by Product Type

• Epilepsy By Stage and Product Type

• Epilepsy Assessment by Route of Administration

• Epilepsy By Stage and Route of Administration

• Epilepsy Assessment by Molecule Type

• Epilepsy by Stage and Molecule Type

DelveInsight’s Epilepsy Report covers around 90+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies

Some of the key companies in the Epilepsy Therapeutics Market include:

Key companies developing therapies for Epilepsy are – Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, H. Lundbeck A/S, Spark Therapeutics, Equilibre Biopharmaceuticals, ES Therapeutics, Supernus Pharmaceuticals, Inc., MGC Pharmaceuticals, Engrail Therapeutics INC, SK biopharmaceuticals, Longboard Pharmaceuticals, Janssen Research & Development, LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, LLC, Neurona Therapeutics, Praxis Precision Medicines, UCB Pharma, Receptor Life Sciences, NeuroPro Therapeutics, Inc., Avicanna, Amring Pharmaceuticals Inc., Ovid Therapeutics, Addex Therapeutics, IAMA Therapeutics, CODA Biotherapeutics, Cerebral Therapeutics, Engrail Therapeutics, and others.

Epilepsy Pipeline Analysis:

The Epilepsy pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.

• Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Epilepsy drugs and therapies

Epilepsy Pipeline Market Drivers

• Rising awareness and strategic alliance, increasing launch of novel drugs, high burden of epilepsy are some of the important factors that are fueling the Epilepsy Market.

Epilepsy Pipeline Market Barriers

• However, loss of patent protection for branded drugs, high cost of treatment and other factors are creating obstacles in the Epilepsy Market growth.

Scope of Epilepsy Pipeline Drug Insight

• Coverage: Global

• Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others

• Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others

• Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies

• Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers

Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trials

Table of Contents

1. Epilepsy Report Introduction

2. Epilepsy Executive Summary

3. Epilepsy Overview

4. Epilepsy- Analytical Perspective In-depth Commercial Assessment

5. Epilepsy Pipeline Therapeutics

6. Epilepsy Late Stage Products (Phase II/III)

7. Epilepsy Mid Stage Products (Phase II)

8. Epilepsy Early Stage Products (Phase I)

9. Epilepsy Preclinical Stage Products

10. Epilepsy Therapeutics Assessment

11. Epilepsy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Epilepsy Key Companies

14. Epilepsy Key Products

15. Epilepsy Unmet Needs

16 . Epilepsy Market Drivers and Barriers

17. Epilepsy Future Perspectives and Conclusion

18. Epilepsy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/